Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Director Declaration

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,420.00    -212.00 (-1.56%)
Bid:
13,414.00
Ask:
13,418.00
Spread: 4.00 (0.03%)
Market Cap: £208.13b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Director Declaration

21 May 2025 13:45

RNS Number : 4890J
AstraZeneca PLC
21 May 2025
 

21 May 2025

 

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed a director of Agilent Technologies Inc. with effect from 21 May 2025.

 

This announcement is made pursuant to Listing Rule 6.4.9 (2).

 

AstraZeneca 

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca 

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Matthew BowdenCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNVBLFLEELBBBE
12345678910
Date   Source Headline
4th Jul 20257:00 amRNSImfinzi approved in the EU for bladder cancer
1st Jul 20253:00 pmRNSTotal Voting Rights
24th Jun 20257:00 amRNSDatroway approved in US for EGFRm lung cancer
17th Jun 202511:45 amRNSHolding(s) in Company
13th Jun 20259:30 amRNSAstraZeneca enters into collaboration with CSPC
12th Jun 20253:00 pmRNSDirector/PDMR Shareholding
6th Jun 20257:00 amRNSFixed-duration Calquence approved in EU for 1L CLL
2nd Jun 20253:05 pmRNSBlock listing Interim Review
2nd Jun 20253:00 pmRNSTotal Voting Rights
27th May 20257:00 amRNSImfinzi recommended in EU for bladder cancer
23rd May 202510:00 amRNSDirector/PDMR Shareholding
21st May 20251:45 pmRNSDirector Declaration
20th May 20257:00 amRNSAcquisition of EsoBiotec completed
9th May 20257:00 amRNSImfinzi improved DFS in early bladder cancer
7th May 20257:30 amRNSEnhertu improved pCR in early-stage breast cancer
6th May 20257:00 amRNSCalquence combination approved in EU for 1L MCL
2nd May 20257:00 amRNSBreztri met primary endpoints in Ph3 asthma trials
1st May 20254:00 pmRNSDirector/PDMR Shareholding
1st May 20253:00 pmRNSTotal Voting Rights
29th Apr 20257:10 amRNSFixed-duration Calquence recommended in EU for CLL
29th Apr 20257:05 amRNSUpdate on CAPItello-280 Phase III trial
29th Apr 20257:00 amRNS1st Quarter Results
22nd Apr 20257:00 amRNSEnhertu combination improved PFS in 1L HER2+ mBC
11th Apr 20255:30 pmRNSResult of AGM
4th Apr 20257:05 amRNSImfinzi approved in EU for AEGEAN
4th Apr 20257:00 amRNSEnhertu approved in EU in post-ET breast cancer
1st Apr 20253:00 pmRNSTotal Voting Rights
31st Mar 20257:05 amRNSCalquence recommended for EU approval in 1L MCL
31st Mar 20257:00 amRNSImfinzi approved in the US for bladder cancer
21st Mar 202510:58 amRNSAZN invests $2.5bn in Beijing R&D & manufacturing
17th Mar 20257:10 amRNSEneboparatide Phase III trial met primary endpoint
17th Mar 20257:05 amRNSImfinzi approved in EU for limited-stage SCLC
17th Mar 20257:00 amRNSAstraZeneca to acquire EsoBiotec
12th Mar 20256:00 pmRNSHolding(s) in Company
7th Mar 20253:00 pmRNSDirector/PDMR Shareholding
7th Mar 202511:00 amRNSNotice of AGM
7th Mar 20257:00 amRNSImfinzi improved EFS in early-stage gastric cancer
6th Mar 20253:00 pmRNSDirector/PDMR Shareholding
5th Mar 20253:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20253:00 pmRNSTotal Voting Rights
3rd Mar 20257:00 amRNSImfinzi recommended for EU approval for AEGEAN
28th Feb 20251:00 pmRNSEnhertu recommended in EU in post-ET breast cancer
26th Feb 20257:00 amRNSCamizestrant improved PFS in 1L HR+ breast cancer
19th Feb 20257:00 amRNSFiling of Form 20-F with SEC
18th Feb 20252:00 pmRNSHolding(s) in Company
18th Feb 202511:00 amRNSAnnual Financial Report
18th Feb 20257:00 amRNSDirectorate Change
6th Feb 20257:00 amRNSFinal Results
3rd Feb 20255:00 pmRNSTotal Voting Rights
3rd Feb 20257:00 amRNSImfinzi recommended for EU approval for LS-SCLC
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
EDIN
Edinburgh Investment Trust PLC
LSE
0.76%
SST
Scottish Oriental Smaller Companies Trust
LSE
0.38%
BOOM
Audioboom Grp.
LSE
-1.75%
SDV
Chelvertn Uk
LSE
-0.91%
EQLS
Equals Gp
LSE
0.00%
Trending
BSFA
Bio-Sustainable Future Enterprises
LSE
0.00%
ITM
Itm Power
LSE
-9.22%
ECR
ECR Minerals
LSE
-8.33%
FORG
Forgent
LSE
8.82%
RCGH
Rc365 Holding
LSE
-35.00%